Stefan Pushkov

Stefan Pushkov

Auto-generated profile, based on publicly available information

Stefan Pushkov

Insilico Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2021 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
VNVladimir Naumov
Vladimir Naumov
ELEugene Lane
Eugene Lane
SPStefan Pushkov
Stefan Pushkov
EKEkaterina Kozlova
Ekaterina Kozlova
KRKonstantin Romantsov
Konstantin Romantsov
EPEvgeny Putin
Evgeny Putin
Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in December 2019 in Wuhan, China. It was quickly established that both the symptoms and the disease severity may vary from one case to another and several strains of SARS-CoV-2 have been identified. To gain a better understanding of the wide variety of SARS-CoV-2 strains and their associated symptoms, thousands of SARS-CoV-2 genomes have been sequenced in dozens of countries. In this article, we introduce COVIDomic, a multi-omics online platform designed to facilitate the analysis and interpretation of the large amount of health data collected from patients with COVID-19. The COVIDomic platform provides a comprehensive set of bioinformatic tools for the multi-modal metatranscriptomic data analysis of COVID-19 patients to determine the origin of the coronavirus strain and the expected severity of the disease. An integrative analytical workflow, which includes microbial pathogens community analysis, COVID-19 genetic epidemiology and patient stratification, allows to analyze the presence of the most common microbial organisms, their antibiotic resistance, the severity of the infection and the set of the most probable geographical locations from which the studied strain could have originated. The online platform integrates a user friendly interface which allows easy visualization of the results. We envision this tool will not only have immediate implications for management of the ongoing COVID-19 pandemic, but will also improve our readiness to respond to other infectious outbreaks.

30 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AZAlex Zhavoronkov
Alex Zhavoronkov
VAVladimir Aladinskyi
Vladimir Aladinskyi
AAAlex Aliper
Alex Aliper
ZMZulfat Miftakhutdinov
Zulfat Miftakhutdinov
MRMathieu Reymond
Mathieu Reymond
FGFedor Galkin
Fedor Galkin
The aging clock paradigm has yielded dozens of specialist models that can estimate chronological age or mortality from virtually any biodata type. Yet each such model operates within a fixed modality, relies on a predetermined feature set, and produces limited biological interpretation. Here, we report Longevity-LLM v0.1, a Qwen3-14B model fine-tuned through supervised and reinforcement learning regimes on DNA methylation, proteomics, clinical biomarker, and RNA expression data. Longevity-LLM achieves high ranks in the recently announced Longevity Bench, including such tasks as cancer survival and RNA- or proteome-based age prediction. After reinforcement fine-tuning, the model achieved a 4.34-year MAE in epigenetic age prediction, surpassing the Horvath multi-tissue clock. In addition to age prediction, Longevity-LLM can carry out numerous other tasks, including proteomic profile generation, for which it significantly outperforms all frontier LLMs. These results demonstrate that a single modestly sized LLM can match or replace purpose-built aging clocks across data modalities. This work constitutes an interim report from the initial sprint of our Multi-Modal AI Gym for Science (MMAI), an initiative dedicated to building foundation models for drug discovery and aging research.

13 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AZAlex Zhavoronkov
Alex Zhavoronkov
DSDenis Sidorenko
Denis Sidorenko
VNVladimir Naumov
Vladimir Naumov
SPStefan Pushkov
Stefan Pushkov
DZDiana Zagirova
Diana Zagirova
FGFedor Galkin
Fedor Galkin
Aging is a core biological process observed in most species and tissues, which is studied with a vast array of technologies. We argue that the abilities of AI systems to emulate aging and to accurately interpret biodata in its context are the key criteria to judge an LLM’s utility in biomedical research. Here, we present LongevityBench — a collection of tasks designed to assess whether foundation models grasp the fundamental principles of aging biology and can use low-level biodata to arrive at phenotype-level conclusions. The benchmark covers a variety of prediction targets including human time-to-death, mutations’ effect on lifespan, and age-dependent omics patterns. It spans all common biodata types used in longevity research: transcriptomes, DNA methylation profiles, proteomes, genomes, clinical blood tests and biometrics, as well as natural language annotations. After ranking state-of-the-art foundation models using LongevityBench, we highlight their weaknesses and outline procedures to maximize their utility in aging research and life sciences.